Posted by Michael Wonder on 13 Apr 2026
Dupixent (dupilumab) approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13 April 2026 - Regeneron Pharmaceuticals and Sanofi today announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate to severe chronic spontaneous urticaria in children aged 2 to 11 years with inadequate response to histamine-1 antihistamines and who are naïve to anti-immunoglobulin E therapy for chronic spontaneous urticaria.
This expands the previous approval in the EU for adults and adolescents aged 12 years and older with chronic spontaneous urticaria, a chronic, inflammatory skin disease that causes sudden and debilitating hives and recurring itch.
